149 related articles for article (PubMed ID: 23065656)
21. The potential of enzastaurin to enhance platelet aggregation and growth factor secretion: implications for cancer cell survival.
Lesyk G; Fong T; Ruvolo PP; Jurasz P
J Thromb Haemost; 2015 Aug; 13(8):1514-20. PubMed ID: 25990653
[TBL] [Abstract][Full Text] [Related]
22. Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.
Crump M; Leppä S; Fayad L; Lee JJ; Di Rocco A; Ogura M; Hagberg H; Schnell F; Rifkin R; Mackensen A; Offner F; Pinter-Brown L; Smith S; Tobinai K; Yeh SP; Hsi ED; Nguyen T; Shi P; Hahka-Kemppinen M; Thornton D; Lin B; Kahl B; Schmitz N; Savage KJ; Habermann T
J Clin Oncol; 2016 Jul; 34(21):2484-92. PubMed ID: 27217449
[TBL] [Abstract][Full Text] [Related]
23. A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers.
Keith RL; Blatchford PJ; Merrick DT; Bunn PA; Bagwell B; Dwyer-Nield LD; Jackson MK; Geraci MW; Miller YE
Cancer Prev Res (Phila); 2019 Oct; 12(10):721-730. PubMed ID: 31308004
[TBL] [Abstract][Full Text] [Related]
24. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.
Socinski MA; Raju RN; Stinchcombe T; Kocs DM; Couch LS; Barrera D; Rousey SR; Choksi JK; Jotte R; Patt DA; Periman PO; Schlossberg HR; Weissman CH; Wang Y; Asmar L; Pritchard S; Bromund J; Peng G; Treat J; Obasaju CK
J Thorac Oncol; 2010 Dec; 5(12):1963-9. PubMed ID: 21102260
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Vogl UM; Berger W; Micksche M; Pirker C; Lamm W; Pichelmeyer O; Zielinski CC; Schmidinger M
Cancer Lett; 2009 May; 277(2):218-26. PubMed ID: 19171421
[TBL] [Abstract][Full Text] [Related]
26. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
[TBL] [Abstract][Full Text] [Related]
27. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
Podar K; Raab MS; Zhang J; McMillin D; Breitkreutz I; Tai YT; Lin BK; Munshi N; Hideshima T; Chauhan D; Anderson KC
Blood; 2007 Feb; 109(4):1669-77. PubMed ID: 17023575
[TBL] [Abstract][Full Text] [Related]
28. Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects.
Welch PA; Sinha VP; Cleverly AL; Darstein C; Flanagan SD; Musib LC
J Clin Pharmacol; 2007 Sep; 47(9):1138-51. PubMed ID: 17766700
[TBL] [Abstract][Full Text] [Related]
29. Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.
Dudek AZ; Zwolak P; Jasinski P; Terai K; Gallus NJ; Ericson ME; Farassati F
Invest New Drugs; 2008 Feb; 26(1):13-24. PubMed ID: 17805485
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Morschhauser F; Seymour JF; Kluin-Nelemans HC; Grigg A; Wolf M; Pfreundschuh M; Tilly H; Raemaekers J; van 't Veer MB; Milpied N; Cartron G; Pezzutto A; Spencer A; Reyes F; Dreyling M
Ann Oncol; 2008 Feb; 19(2):247-53. PubMed ID: 17906297
[TBL] [Abstract][Full Text] [Related]
31. A phase I trial of enzastaurin in patients with recurrent gliomas.
Kreisl TN; Kim L; Moore K; Duic P; Kotliarova S; Walling J; Musib L; Thornton D; Albert PS; Fine HA
Clin Cancer Res; 2009 May; 15(10):3617-23. PubMed ID: 19417015
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
[TBL] [Abstract][Full Text] [Related]
33. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia.
Lam S; MacAulay C; Le Riche JC; Dyachkova Y; Coldman A; Guillaud M; Hawk E; Christen MO; Gazdar AF
J Natl Cancer Inst; 2002 Jul; 94(13):1001-9. PubMed ID: 12096085
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of glycogen synthase kinase-3 increases the cytotoxicity of enzastaurin.
Rovedo MA; Krett NL; Rosen ST
J Invest Dermatol; 2011 Jul; 131(7):1442-9. PubMed ID: 21471986
[TBL] [Abstract][Full Text] [Related]
35. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
Querfeld C; Rizvi MA; Kuzel TM; Guitart J; Rademaker A; Sabharwal SS; Krett NL; Rosen ST
J Invest Dermatol; 2006 Jul; 126(7):1641-7. PubMed ID: 16645590
[TBL] [Abstract][Full Text] [Related]
36. Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.
Shimokawa T; Seike M; Soeno C; Uesaka H; Miyanaga A; Mizutani H; Kitamura K; Minegishi Y; Noro R; Okano T; Yoshimura A; Gemma A
Br J Cancer; 2012 Feb; 106(5):867-75. PubMed ID: 22333600
[TBL] [Abstract][Full Text] [Related]
37. Protein kinase C β inhibition by enzastaurin leads to mitotic missegregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN).
Ouaret D; Larsen AK
Cell Cycle; 2014; 13(17):2697-706. PubMed ID: 25486357
[TBL] [Abstract][Full Text] [Related]
38. Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.
Vergote IB; Chekerov R; Amant F; Harter P; Casado A; Emerich J; Bauknecht T; Mansouri K; Myrand SP; Nguyen TS; Shi P; Sehouli J
J Clin Oncol; 2013 Sep; 31(25):3127-32. PubMed ID: 23897968
[TBL] [Abstract][Full Text] [Related]
39. A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.
Lam S; Mandrekar SJ; Gesthalter Y; Allen Ziegler KL; Seisler DK; Midthun DE; Mao JT; Aubry MC; McWilliams A; Sin DD; Shaipanich T; Liu G; Johnson E; Bild A; Lenburg ME; Ionescu DN; Mayo J; Yi JE; Tazelaar H; Harmsen WS; Smith J; Spira AE; Beane J; Limburg PJ; Szabo E;
Cancer Prev Res (Phila); 2016 Dec; 9(12):906-914. PubMed ID: 27658890
[TBL] [Abstract][Full Text] [Related]
40. Protein kinase Cbeta is an effective target for chemoprevention of colon cancer.
Fields AP; Calcagno SR; Krishna M; Rak S; Leitges M; Murray NR
Cancer Res; 2009 Feb; 69(4):1643-50. PubMed ID: 19221092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
